Toward a treat-to-target strategy in juvenile dermatomyositis: what are the suitable targets and optimal timing of their achievement? [0.03%]
以治疗目标为导向的幼年皮肌炎策略：合适的靶点及其最佳实现时间是什么？
Jayne M MacMahon,Angelo Ravelli,Ana Isabel Rebollo-Giménez et al.
Jayne M MacMahon et al.
Introduction: Juvenile dermatomyositis (JDM) is a rare autoimmune condition. The treat-to-target (T2T) strategy has garnered interest in paediatric rheumatology. It is based on defining clear therapeutic targets, with fre...
Relapse Rate After Glucocorticoid-free Remission in patients with Idiopathic Inflammatory Myopathies and Validation of the International Myositis Assessment and Clinical Studies Group (IMACS) Criteria for Complete Clinical Response and Worsening [0.03%]
糖皮质激素诱导的DM/PM患者临床缓解后的复发率及国际肌炎评价和临床研究组（IMACS）完全临床缓解与疾病加重标准验证的研究
Hideaki Tsuji,Fabricio Espinosa-Ortega,Irene Peralta Garcia et al.
Hideaki Tsuji et al.
Objectives: Our aim was to explore maintenance of glucocorticoid-free remission in patients with idiopathic inflammatory myopathy (IIM). Secondary, we examined the performance of the International Myositis Assessment and ...
2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus [0.03%]
2025年美国风湿病学会(SRAP)系统性红斑狼疮治疗指南
Lisa R Sammaritano,Anca Askanase,Bonnie L Bermas et al.
Lisa R Sammaritano et al.
Objective: To provide evidence-based and expert guidance for the treatment and management of non-renal systemic lupus erythematosus (SLE); treatment and management of lupus nephritis are addressed in a separate guideline....
Claudia Günther
Claudia Günther
Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase III, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial [0.03%]
托法替尼治疗青少年特发性关节炎：一项III期随机双盲安慰剂对照减撤试验中患者的报告结局
Hermine I Brunner,Ekaterina Alexeeva,Marcia Bandeira et al.
Hermine I Brunner et al.
Objective: Juvenile idiopathic arthritis (JIA) is associated with impaired overall health-related quality of life (HRQoL). We evaluated the impact of tofacitinib on patient-reported outcomes (PROs) in patients with JIA. ...
Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand? [0.03%]
lupus肾炎病理的生物标志物：我们目前处在什么位置？
Valentina Querin,Leonardo Palazzo,Agnes B Fogo et al.
Valentina Querin et al.
Objective: Lupus nephritis (LN) is characterized by a variable disease course, necessitating continuous monitoring. There is an urgent need to identify non-invasive biomarkers. By reviewing and critically assessing the qu...
HLA-DQA1*01:02 is associated with antibody multi-reactivity with citrulline-containing type II collagen epitopes while HLA-DRB1*04:01 is associated with more private antibody reactivity with citrulline-containing IgG epitopes in rheumatoid arthritis [0.03%]
HLA-DQA1*01:02与抗含瓜氨酸Ⅱ型胶原表位抗体多反应性相关，而HLA-DRB1*04:01与抗含瓜氨酸IgG表位抗体的私人反应性增加有关：类风湿关节炎的一项研究
S Janna Bashar,Courtney B Myhr,Adam H Titi et al.
S Janna Bashar et al.
Objective: Anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) can be promiscuous, with cross-reactive binding to many antigens containing short motifs, or private with little cross-reactivity. Also...
letter to the Editor, Nociplasticity, rather than fibromyalgia, best conceptualizes symptoms not linked to well-defined organ disease in systemic lupus erythematosus: Comment on the article by Pisetsky, et al [0.03%]
关于Pisetsky等的文章的来信：非器质性疾病相关症状应用“痛觉可塑性”而非“纤维肌痛”更好：评论文章
Don L Goldenberg
Don L Goldenberg
Diagnostic implications and correlates of plasma ADA2 activity and ADA2 variants [0.03%]
ADA2血浆活性和基因变异的诊断意义及临床相关性分析
Jian Yue,Courtney E LeSon,Casey A Rimland et al.
Jian Yue et al.
Objectives: Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease manifested as polyarteritis nodosa, stroke, and bone marrow failure. Leveraging an international cohort of 200 DADA2 cases, w...
The efficacy of Telitacicept in Childhood-onset Systemic Lupus Erythematosus: a prospective multi-center cohort study with IPTW-adjusted comparison to a historical control group treated with Belimumab [0.03%]
泰利菲塞肽治疗儿童期起病系统性红斑狼疮疗效：与既往贝利尤单抗治疗的队列历史对照研究及逆概率加权分析
Chong Luo,Shu Su,Jingyue Liu et al.
Chong Luo et al.
Objective: The therapeutic effects of Telitacicept combined with standard of care (SoC) in childhood-onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with Be...